Week 5 Pharmacology Discussion

  • Uncategorized


Week5 Pharmacology Discussion

Week5 Pharmacology Discussion

Dementiais not a specific health condition. It is a general term thatdescribes a decline in thinking or mental ability of an individual. Adeterioration is mental ability is considered to be dementia if ithas a direct impact on the daily life of an individual. Alzheimer’sdisease is the most common type of dementia accounting for about fourout of five cases. The treatment of dementia is largely influenced bythe cause of mental ability decline (Andrews, 2015). SinceAlzheimer’s disease has no cure and is the most common type ofdementia, the condition has no cure. Cognitive therapies are the mostrecommended approaches in the management of dementia. However, thereare some medications that can be prescribed to dementia patients.These drugs are used to treat cognitive symptoms but have no impacton the progress of the condition (Bond et al, 2012). The most commontype medications are acetylcholinesterase inhibitors, methylaspartate receptors blockers, vitamins supplements and antidepressantdrugs. Age is an important factor in dementia (Shea, 2012). Majorityof individuals suffering from dementia are above the age of 65 years.Although younger individuals can also be affected by the disease, agehas no significant impact on the management of the disease.Nonetheless, dementia has more impact when it affects relativelyyoung people (Larson et al, 2013). While old people are generally inretirement, dementia in younger people has a greater impact on theirlives. This means that younger patients are less likely to beprovided with adequate support. Additionally, since it is a diseasefor the elderly, there is a higher likelihood that dementia inyounger individuals will be misdiagnosed or diagnosed late (Shea,2012). Increased awareness of dementia in younger people and theirspecial needs is critical.


Shea,T. (2012). Dementia.New York: Rosen Pub.

Bond,M et al (2012). &quotThe effectiveness and cost-effectiveness ofdonepezil, galantamine, rivastigmine and memantine for the treatmentof Alzheimer`s disease: a systematic review and economic model.”Healthtechnology assessment,16 (21): 1–470.

Larson,E. B. et al (2013). &quotNew insights into the dementia epidemic.”TheNew England Journal of Medicine 369(24): 2275–7.

Andrews,J. (2015). Dementia:the one-stop guide.London: Profile Books.

Close Menu